Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity.
Adenoviridae
/ genetics
Animals
Antibodies, Neutralizing
Antibodies, Viral
Humans
Immunity, Innate
Immunization
Immunoglobulin A
Mice
Mice, Inbred BALB C
Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus Vaccines
/ genetics
Vaccination
Viral Fusion Proteins
/ genetics
Viral Vaccines
Weight Loss
IgA
RSV (respiratory syncytial virus)
TRM
adenoviral (Ad) vector
mucosal
natural immunity
tissue-resident memory T cells
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
04
2022
accepted:
07
07
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Respiratory syncytial virus (RSV) infections are the leading cause of severe respiratory illness in early infancy. Although the majority of children and adults mount immune responses against RSV, recurrent infections are frequent throughout life. Humoral and cellular responses contribute to an effective immunity but also their localization at respiratory mucosae is increasingly recognized as an important factor. In the present study, we evaluate a mucosal vaccine based on an adenoviral vector encoding for the RSV fusion protein (Ad-F), and we investigate two genetic adjuvant candidates that encode for Interleukin (IL)-1β and IFN-β promoter stimulator I (IPS-1), respectively. While vaccination with Ad-F alone was immunogenic, the inclusion of Ad-IL-1β increased F-specific mucosal immunoglobulin A (IgA) and tissue-resident memory T cells (T
Identifiants
pubmed: 36003372
doi: 10.3389/fimmu.2022.920256
pmc: PMC9394428
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin A
0
Respiratory Syncytial Virus Vaccines
0
Viral Fusion Proteins
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
920256Informations de copyright
Copyright © 2022 Maier, Fuchs, Irrgang, Wißing, Beyerlein, Tenbusch and Lapuente.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunohorizons. 2021 Feb 3;5(2):59-69
pubmed: 33536235
Nat Commun. 2015 Dec 21;6:10224
pubmed: 26687547
Viruses. 2022 Feb 17;14(2):
pubmed: 35216012
J Infect Dis. 1991 Apr;163(4):693-8
pubmed: 2010624
PLoS Pathog. 2016 Jul 20;12(7):e1005754
pubmed: 27438481
J Virol. 2002 Nov;76(22):11561-9
pubmed: 12388717
Nat Med. 2006 Aug;12(8):905-7
pubmed: 16862151
Front Immunol. 2019 Sep 24;10:2255
pubmed: 31608062
J Virol. 2010 Dec;84(24):12703-12
pubmed: 20881038
J Immunother Cancer. 2021 Nov;9(11):
pubmed: 34772757
J Leukoc Biol. 2014 Feb;95(2):215-24
pubmed: 24006506
Cell Rep. 2017 Sep 19;20(12):2921-2934
pubmed: 28930685
J Infect Dis. 2022 Aug 26;226(3):396-406
pubmed: 33400792
Cancer Res. 2011 Jan 15;71(2):328-38
pubmed: 21224355
Mucosal Immunol. 2022 Apr;15(4):717-729
pubmed: 35260804
J Exp Med. 2015 May 4;212(5):699-714
pubmed: 25897172
J Med Virol. 1988 Oct;26(2):153-62
pubmed: 3183639
Sci Immunol. 2019 Mar 8;4(33):
pubmed: 30850393
Mucosal Immunol. 2019 Sep;12(5):1244-1255
pubmed: 31358860
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14046-51
pubmed: 18780793
Cell Host Microbe. 2022 Jan 12;30(1):41-52.e5
pubmed: 34879230
Nat Med. 2009 Jan;15(1):34-41
pubmed: 19079256
Mucosal Immunol. 2020 May;13(3):507-517
pubmed: 31844172
J Immunol. 2012 Sep 15;189(6):2702-6
pubmed: 22896631
Front Microbiol. 2019 May 03;10:873
pubmed: 31130923
Nat Commun. 2021 Nov 26;12(1):6871
pubmed: 34836955
Mucosal Immunol. 2018 Jan;11(1):249-256
pubmed: 28537249
Vaccine. 2021 Feb 22;39(8):1248-1256
pubmed: 33509697
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7119-24
pubmed: 19359475
NPJ Vaccines. 2020 Jul 23;5(1):64
pubmed: 32714571
Front Immunol. 2020 Oct 06;11:572747
pubmed: 33123150
Nat Rev Immunol. 2007 Oct;7(10):803-15
pubmed: 17893694
Mol Ther Methods Clin Dev. 2015 May 20;2:15018
pubmed: 26015988
J Virol. 2009 Dec;83(23):12601-10
pubmed: 19776123
Mucosal Immunol. 2018 Jul;11(4):1265-1278
pubmed: 29545648
J Virol. 2014 Dec;88(24):13990-4001
pubmed: 25253340
Proc Natl Acad Sci U S A. 1985 Jun;82(12):4075-9
pubmed: 3858865
Hum Vaccin Immunother. 2018 Jun 3;14(6):1351-1361
pubmed: 29425074
Virology. 2020 Nov;550:21-26
pubmed: 32866728
J Clin Microbiol. 1988 Aug;26(8):1595-7
pubmed: 2459154
J Virol. 1986 Mar;57(3):721-8
pubmed: 2419587
NPJ Vaccines. 2019 Dec 20;4:54
pubmed: 31885877
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
J Clin Invest. 2020 Jan 2;130(1):523-538
pubmed: 31815739
J Virol. 2017 Feb 28;91(6):
pubmed: 28077630
Am J Epidemiol. 1969 Apr;89(4):422-34
pubmed: 4305198
Nature. 2021 Dec;600(7889):379-380
pubmed: 34893769
Nat Immunol. 2013 Mar;14(3):246-53
pubmed: 23314004
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14
pubmed: 9482916
Vaccine. 2018 May 3;36(19):2712-2720
pubmed: 29628150
JCI Insight. 2016 Jul 7;1(10):
pubmed: 27468427
J Virol. 2011 Feb;85(3):1370-83
pubmed: 21106745
Thorax. 2010 Dec;65(12):1045-52
pubmed: 20581410
PLoS Pathog. 2022 Feb 2;18(2):e1010272
pubmed: 35108347
Vaccine. 2001 Oct 15;20 Suppl 1:S27-31
pubmed: 11587806
J Infect Dis. 2004 Jul 15;190(2):373-8
pubmed: 15216475
PLoS One. 2020 Apr 3;15(4):e0231138
pubmed: 32243477
PLoS Pathog. 2018 Jan 2;14(1):e1006810
pubmed: 29293660
Pediatr Res. 2002 Sep;52(3):363-7
pubmed: 12193668
Am J Respir Crit Care Med. 2015 May 1;191(9):1040-9
pubmed: 25730467
Biotherapy. 1989;1(4):355-9
pubmed: 2701649
J Exp Med. 2013 Mar 11;210(3):491-502
pubmed: 23460726
Annu Rev Immunol. 2009;27:519-50
pubmed: 19302047
JAMA. 2003 Jan 8;289(2):179-86
pubmed: 12517228